Sun Pharmaceutical Industries Limited has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection in the country. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is indicated for chronic weight management in adults, to be used as an adjunct to a reduced-calorie diet and increased physical activity. This development marks a significant step in expanding access to GLP-1–based therapies in the Indian pharmaceutical market.
The company plans to launch the generic semaglutide injection under the brand name Noveltreat after the expiry of the semaglutide patent in India. The approval has been granted following a detailed review of a Phase III clinical trial conducted within the country, underscoring regulatory clearance based on India-specific clinical data. Noveltreat will be available in five dose strengths—0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL—with a recommended maintenance dose of 2.4 mg administered once weekly.
Noveltreat will be offered through an easy-to-use prefilled pen, designed to support accurate dosing and improve patient convenience. The once-weekly administration format aligns with existing global treatment practices for semaglutide, potentially supporting better adherence among patients undergoing long-term weight management therapy.
Separately, in December 2025, Sun Pharma had already received DCGI approval to manufacture and market semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. This formulation is planned to be launched under the brand name Sematrinity, also after the expiry of the semaglutide patent in India.
